Drugs / SCB-1019
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06194318 | Dec 2023 → Feb 2025 | respiratory syncytial virus infectious disease | Clover Biopharmaceuticals AUS Pty | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCB-1019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06194318 ↗ |
| Modality | Vaccine | “The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B).” NCT06194318 ↗ |